Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TransMedics (TMDX) Common Equity (2018 - 2025)

Historic Common Equity for TransMedics (TMDX) over the last 8 years, with Q3 2025 value amounting to $355.2 million.

  • TransMedics' Common Equity rose 6920.73% to $355.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $355.2 million, marking a year-over-year increase of 6920.73%. This contributed to the annual value of $228.6 million for FY2024, which is 6661.78% up from last year.
  • Latest data reveals that TransMedics reported Common Equity of $355.2 million as of Q3 2025, which was up 6920.73% from $318.1 million recorded in Q2 2025.
  • TransMedics' 5-year Common Equity high stood at $355.2 million for Q3 2025, and its period low was $50.9 million during Q2 2022.
  • In the last 5 years, TransMedics' Common Equity had a median value of $159.5 million in 2024 and averaged $165.7 million.
  • In the last 5 years, TransMedics' Common Equity plummeted by 4277.67% in 2022 and then skyrocketed by 22152.4% in 2023.
  • Quarter analysis of 5 years shows TransMedics' Common Equity stood at $67.9 million in 2021, then soared by 176.14% to $187.4 million in 2022, then dropped by 26.78% to $137.2 million in 2023, then skyrocketed by 66.62% to $228.6 million in 2024, then soared by 55.38% to $355.2 million in 2025.
  • Its Common Equity stands at $355.2 million for Q3 2025, versus $318.1 million for Q2 2025 and $266.3 million for Q1 2025.